



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Shibo Jiang
shibojiang@fudan.edu.cn
Naru Zhang
zhangnr@zucc.edu.cn

SPECIALTY SECTION
This article was submitted to
Clinical Microbiology,
a section of the journal
Frontiers in Cellular and
Infection Microbiology

RECEIVED 29 July 2022
ACCEPTED 03 August 2022
PUBLISHED 26 August 2022

CITATION
Li K, Ji Q, Jiang S and Zhang N (2022)
Corrigendum: Advancement in the
development of therapeutics against
Zika virus infection.
Front. Cell. Infect. Microbiol.
12:1006226.
doi: 10.3389/fcimb.2022.1006226

COPYRIGHT
© 2022 Li, Ji, Jiang and Zhang. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: Advancement in the development of therapeutics against Zika virus infection

Kangchen Li¹, Qianting Ji¹, Shibo Jiang^{2*} and Naru Zhang^{1*}

¹Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China, ²Key Laboratory of Medical Molecular Virology of Ministry of Education (MOE), National Health Commission (NHC) and Chinese Academy of Medical Sciences (CAMS), School of Basic Medical Sciences and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

KEYWORDS

Zika virus, pathogenesis, therapeutics, NS2B–NS3 protease inhibitors, NS3 protease inhibitors, NS5 protein inhibitors, E protein inhibitors, host protein inhibitors

A corrigendum on

Advancement in the development of therapeutics against zika virus infection

by Li K, Ji Q, Jiang S, and Zhang N (2022). *Front. Cell. Infect. Microbiol.* 12:946957.
doi: 10.3389/fcimb.2022.946957

Text Correction

In the published article, there was an error. [There is a spelling mistake by writing “NS5 protease inhibitors” in key words on page 1 and in one of the subheadings named “NS5 Protease Inhibitors” on page 4].

A correction has been made to [“Key words” and “THE DEVELOPMENT OF ANTI-ZIKV THERAPEUTICS”], [NS5 Protease Inhibitors], [the subheading of “NS5 Protease Inhibitors”]. This sentence previously stated: “[NS5 Protease Inhibitors]”

The corrected sentence appears below: “[NS5 Protein Inhibitors]”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.